Use of the Jarvik 2000 continuous flow left ventricular assist device for acute myocardial infarction and cardiogenic shock.

Division of Cardiothoracic Surgery, University of North Carolina, Chapel Hill, North Carolina 27599-7065, USA.
The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation (Impact Factor: 5.61). 08/2007; 26(7):756-8. DOI: 10.1016/j.healun.2007.04.011
Source: PubMed

ABSTRACT Several strategies for circulatory support have been successfully utilized as bridges to recovery or transplantation after acute myocardial infarction and cardiogenic shock. We report the novel use of a continuous flow left ventricular assist device (LVAD) for successful recovery and bridging to transplantation in a patient who had massive anterior wall myocardial infarction.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The development of a simple mapping technology for viewing the activation wavefronts of rodent hearts is currently ongoing. The successful development of an electrophysiologic (EP) electrode array biosensor for rodent hearts has been the foundation of this work. Our goal is to develop a simple method to process EP data obtained by the biosensor and present the data in a graphical format suitable for additional quantitative and qualitative analysis
    BMES/EMBS Conference, 1999. Proceedings of the First Joint; 02/1999
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Given the limited availability of donor hearts, ventricular assist device (VAD) therapy is fast becoming an accepted alternative treatment strategy to treat end-stage heart failure. The field of mechanical ventricular assistance is littered with novel and unique ideas either based on volume displacement or rotary pump technology, which aim to sufficiently restore cardiac output. However, only a select few have made the transition to the clinical arena. Clinical implants were initially dominated by the FDA approved volume displacement Thoratec HeartMate I, IVAD, and PVAD, whilst Berlin Heart's EXCOR, and Abiomed's BVS5000 and AB5000 offered suitable alternatives. However, limitations associated with an inherently large size and reduced lifetime of these devices stimulated the development and subsequent implantation of rotary blood pump (RBP) technology. Almost all of the reviewed RBPs are clinically available in Europe, whilst many are still undergoing clinical trial in the USA. Thoratec's HeartMate II is currently the only rotary device approved by the FDA, and has supported the highest number of patients to date. This pump is joined by MicroMed Cardiovascular's Heart Assist 5 Adult VAD, Jarvik Heart's Jarvik 2000 FlowMaker and Berlin Heart's InCOR as the axial flow devices under investigation in the USA. More recently developed radial flow devices such as WorldHeart's Levacor, Terumo's DuraHeart, and HeartWare's HVAD are increasing in their clinical trial patient numbers. Finally CircuLite's Synergy and Abiomed's Impella are two mixed flow type devices designed to offer partial cardiac support to less sick patients. This review provides a brief overview of the volume displacement and rotary devices which are either clinically available, or undergoing the advanced stages of human clinical trials.
    Medical Engineering & Physics 06/2011; 33(9):1041-7. DOI:10.1016/j.medengphy.2011.04.010 · 1.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acute cardiogenic shock has a high mortality. The number of mechanical circulatory assist devices to encounter this life-threatening condition is steadily growing. These devices enable physicians to treat patients with acute cardiac failure refractory to conventional therapy. Mechanical circulatory assist devices are considered last resort to prevent or to reverse a cardiogenic shock. Different centrifugal, pulsatile or nonpulsatile (axial) flow pumps are available to rescue patients in different scenarios. These mechanical circulatory assist devices can be placed percutaneously or surgically as extracorporeal or intracorporeal mechanical circulatory assist devices. Percutaneous mechanical circulatory assist devices are useful to establish rapid life-saving circulatory support under different circumstances. A stabilized patient can then be transferred to an intensive care unit, a catheterization laboratory or an operating room for further assessment and additional treatment with possible change to a mid-term or long-term mechanical circulatory assist device. Percutaneous mechanical circulatory assist devices can be implanted in an emergency setting in patients with acute cardiogenic shock refractory to conventional therapy irrespective of the given location. The choice for a specific mechanical circulatory assist device should be based on the underlying condition and individualized prognosis. Based on the findings of this review, circulatory or axial-flow pumps should be considered first-line devices.
    Current opinion in cardiology 07/2008; 23(4):399-406. DOI:10.1097/HCO.0b013e328303e134 · 2.59 Impact Factor